A FOCUSED CLINICAL ENTRY. A BROADER CNS OPPORTUNITY.
GR1 is advancing toward first-in-human clinical trials, with Friedreich’s ataxia as its initial clinical indication. A separate molecule, GR4, expands Goldenrod’s pipeline into fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), with additional potential in non-opioid pain management.
A PIPELINE DESIGNED AROUND A SHARED PHARMACOLOGY.
FRIEDREICH’S ATAXIA CREATES A FOCUSED ROUTE TO HUMAN VALIDATION.
01
CLEAR NEED
FA is a progressive, multisystem genetic disease. Current therapy does not eliminate the need for additional approaches that address complementary disease biology.
02
BIOLOGICAL FIT
Mitochondrial dysfunction, oxidative stress, and neuroinflammation create a rationale for testing a brain-penetrant PDE4 program.
03
DEVELOPMENT FOCUS
A defined patient community, established clinical measures, and specialist centers can support a focused proof-of-concept strategy.
04
PLATFORM VALUE
Human safety, PK, and PD in the GR1 program can inform expansion well beyond a single rare disease.
GR4: EXPANDING THE POTENTIAL OF PDE4 INHIBITION.
WHAT IT MAY OFFER
A differentiated oral PDE4 inhibitor with therapeutic potential in fibrotic diseases, including IPF, and non-opioid pain management, with the prospect of improved tolerability.
WHAT COMES NEXT
Establishing efficacy in translational models of pulmonary fibrosis, benchmark against approved PDE4 therapy, and further characterize dose response, safety, and exposure. Advancing complementary studies in postoperative pain.
PARTNERSHIP LOGIC
A versatile, independently developable asset offering opportunities for indication-specific, regional, or global pharmaceutical partnerships, while Goldenrod advances its lead CNS program, GR1.